Prominent sickle cell advocate and philathropist Howard Woolley has won a Sickle Cell Outstanding Service Award, presented recently at the 2019 Roland B. Scott Memorial Symposium. Themed “Preparing the next generation of advocates for sickle cell disease healthcare,” the symposium, held at Howard University, featured a…
News
Robert and Tanique Mitchell still remember the moment they found out that their granddaughter, Kiarra Roseburgh, would be born with sickle cell disease (SCD). “We realized that we needed to prepare, and we made two goals as a family: to provide emotional support for Kiarra and to empower ourselves…
IMR-687, an investigational therapy for sickle cell disease, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). It’s currently being evaluated in a Phase 2a trial in the U.S. and U.K. The Fast Track process is meant to get new therapeutics that treat…
RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site was developed by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of…
Novartis‘ Solutions to Empower Patients (STEP) program will fund five nonprofit organizations that address some of the most pressing concerns in the sickle cell disease (SCD) community. Nearly $250,000 will be divided up among patient advocacy organizations and research institutions. Started in 2017, the STEP program funds innovative…
The Phase 2 STRONG-SCD clinical trial evaluating olinciguat as an investigational therapy for sickle cell disease is seeking participants. Olinciguat, being developed by Cyclerion Therapeutics (a spin-off of Ironwood Pharmaceuticals), is an investigational oral therapy that stimulates an enzyme called soluble guanylate cyclase (sGC), known to play a key…
In what’s viewed as a significant step toward addressing unmet needs in California’s sickle cell disease (SCD) community, scientists and policy leaders met recently to discuss proposed legislation, gaps in patient care, and to hear from patients. Called “The Impacts of Sickle Cell Disease in California Legislative Briefing,” the…
With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS) at the…
Backed by a new study suggesting that sickle cell disease (SCD) is common among refugees in Southern Europe, some hematologists are calling for increased screening measures. Specialists are working to determine the extent of blood disorders within the population. They’re also outlining ways to help identify and treat…
Adults with sickle cell disease score worse than their healthy, unaffected siblings on cognitive tests, despite treatment with hydroxyurea, a study reports. The study “Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings” was published in the journal Neuropsychological…
Recent Posts
- Disease burden heavy for SCD patients in US, despite promise of gene therapy
- The conversation we avoid: Telling children they have sickle cell disease
- New study finds distinct molecular signatures in newborns with SCT
- Blood test may improve kidney damage detection in children with SCD
- Understanding the impact of leg ulcers in sickle cell disease
- Asthma seven times more likely in SCD children than in unaffected siblings
- Sickle cell drug at high dose eases anemia symptoms in severe SCD
- Researchers urge more talk on menstrual pain in sickle cell clinics
- Sickle cell patients shifting to adult care visit ER more often: US study
- Early results of trial testing tebapivat in SCD expected later this year